机构:[1]Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China[2]Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Hubei, PR China[3]Department of Liver Surgery, West China Hospital of Sichuan University, No. 37, Guoxue Lane, Chengdu, Sichuan Province, PR China四川大学华西医院[4]University of Chinese Academy of Sciences, Beijing 100049, PR China[5]School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu Province, PR China[6]Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, 180 Fenglin Road, Shanghai 200032, PR China[7]Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China华中科技大学同济医学院附属协和医院[8]College of Life Sciences, Hubei Key Laboratory of Cell Homeostasis, Wuhan University, Wuhan 430072, PR China[9]Department of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA[10]TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, PR China
National Natural Science Foundation of China (824B2088); National Natural Science Foundation of China (82300675); Research Fund of the Health Commission of Hubei Province (WJ2021M255); Cancer Research and Translational Platform Project of Zhongnan Hospital of Wuhan University (ZLYNXM202004); Key Research and Development Program of Hubei Province
(2021BCA114); the Research Fund from the Medical Sci-Tech Innovation Platform of Zhongnan Hospital of Wuhan University
(PTXM2021022); the China National Postdoctoral Program for Innovative Talents (BX20240271); the China Postdoctoral Science Foundation
(2023M742698); the National Natural Science Foundation of China
(82403904); the Natural Science Foundation of Hubei Province
(2024AFB163); the Fundamental Research Funds for the Central Universities (413000553).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类|1 区医学
小类|1 区内分泌学与代谢
最新[2025]版:
大类|1 区医学
小类|1 区内分泌学与代谢
第一作者:
第一作者机构:[1]Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China[2]Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Hubei, PR China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China[2]Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Hubei, PR China[9]Department of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA[10]TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, PR China
推荐引用方式(GB/T 7714):
Xu Kequan,Wu Tiangen,Li Xiaomian,et al.ADH1C maintains the homeostasis of metabolic microenvironment to inhibit steatotic hepatocellular carcinoma[J].Metabolism: Clinical And Experimental.2025,168:156267.doi:10.1016/j.metabol.2025.156267.
APA:
Xu Kequan,Wu Tiangen,Li Xiaomian,Zhang Xiao,Liu Xinyu...&Yuan Yufeng.(2025).ADH1C maintains the homeostasis of metabolic microenvironment to inhibit steatotic hepatocellular carcinoma.Metabolism: Clinical And Experimental,168,
MLA:
Xu Kequan,et al."ADH1C maintains the homeostasis of metabolic microenvironment to inhibit steatotic hepatocellular carcinoma".Metabolism: Clinical And Experimental 168.(2025):156267